Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

Graefe's Archive for Clinical and Experimental Ophthalmology

Volumn 246, Issue 4, 2008, Pages 483-489

  Ahmadieh, Hamid ^a   Ramezani, Alireza ^b   Shoeibi, Nasser ^a   Bijanzadeh, Bijan ^a   Tabatabaei, Ali ^c   Azarmina, Mohsen ^a   Soheilian, Masoud ^a   Keshavarzi, Gholamreza ^c   Mohebbi, Mohammad Reza ^a  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Bevacizumab; Diabetic macular edema; Triamcinolone

Indexed keywords

ANTIGLAUCOMA AGENT; BEVACIZUMAB; CORTICOSTEROID; CYCLOPLEGIC AGENT; TRIAMCINOLONE ACETONIDE; TRIAMHEXAL; UNCLASSIFIED DRUG;

ADULT; AGED; ANTERIOR EYE CHAMBER DISEASE; ARTICLE; CATARACT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DRUG POTENTIATION; EYE INFLAMMATION; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE REACTION; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THICKNESS; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VITREOUS HEMORRHAGE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; VITREOUS BODY;

EID: 41349107607     PISSN: 0721832X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00417-007-0688-0     Document Type: Article

References (25)

1. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487
2. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, Sanchez JG, Wu L, Maia M, Berrocal MH, Solis-Vivanco A, Farah ME; Pan-American Collaborative Retina Study Group (2007) Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology 114:743-750
3. Audren F, Erginay A, Haouchine B, Benosman R, Conrath J, Bergmann JF, Gaudric A, Massin P (2006) Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: 6 month results of a prospective controlled trial. Acta Ophthalmol Scand 84:624-630
4. Audren F, Lecleire-Collet A, Erginay A, Haouchine B, Benosman R, Bergmann JF, Gaudric A, Massin P (2006) Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: Phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol 142:794-799
5. Bakri SJ, Snyder MR, Reid JM, Pulido JS, Singh RJ (2007) Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 114:855-849
6. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA (2005) Intravitreal injection vs sub-tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: A randomized clinical trial. Invest Ophthalmol Vis Sci 46:3845-3849
7. Chylack LT Jr, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL, Friend J, McCarthy D, Wu SY (1993) The lens opacities classification system III. The longitudinal study of cataract study group. Arch Ophthalmol 111:831-836
8. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 103:1796-1806
9. Funatsu H, Yamashita H, Ikeda T, Mimura T, Eguchi S, Hori S (2003) Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 110:1690-1696
10. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S (2002) Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 133:537-543
11. Gillies MC, Sutter FK, Simpson JM, Larsson J, Ali H, Zhu M (2006) Intravitreal triamcinolone for refractory diabetic macular edema. Two- year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113:1533-1538
12. Haritoglou C, Kook D, Neubauer A, Wolf A, Priglinger S, Strauss R, Gandorfer A, Ulbig M, Kampik A (2006) Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 26:999-1005
13. Jonas JB, Martus P, Degenring RF, Kreissig I, Akkoyun I (2005) Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol 123:1338-1343
14. Kiss C, Michels S, Prager F, Weigert G, Geitzenauer W, Schmidt-Erfurth U (2006) Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. Retina 26:877-881
15. Klein R, Klein BE, Moss SE, Davis MD, DeMets DL (1984) The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 91:1464-1474
16. Larsson J, Zhu M, Sutter F, Gillies MC (2005) Relation between reduction of foveal thickness and visual acuity in diabetic macular edema treated with intravitreal triamcinolone. Am J Ophthalmol 139:802-806
17. Lee CM, Olk RJ (1991) Modified grid laser photocoagulation for diffuse diabetic macular edema: Long-term visual results. Ophthalmology 98:1594-1602
18. Macugen Diabetic Retinopathy Study Group (2005) A phase II randomized double- masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 112:1747-1757
19. Martidis A, Duker JS, Greenberg PB, Rogers AH, Puliafito CA, Reichel E, Baumal C (2002) Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920-927
20. Massin P, Audren F, Haouchine B, Erginay A, Bergmann JF, Benosman R, Caulin C, Gaudric A (2004) Intravitreal triamcinolone acetonide for diabetic diffuse macular edema. Preliminary results of a prospective controlled trial. Ophthalmology 111:218-225
21. Patelli F, Fasolino G, Radice P, Russo S, Zumbo G, Di Tizio FM, Frisone G, Marchi S (2005) Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. Retina 25:840-844
22. Qaum T, Xu Q, Joussen AM, Clemens MW, Qin W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD, Adamis AP (2001) VEGF-initiated blood-retinal barrier breakdown in early diabetes. Invest Ophthalmol Vis Sci 42:2408-2413
23. Sutter FK, Simpson JM, Gillies MC (2004) Intravitreal triamcinolone for diabetic macular edema that persists after laser treatment. Three- month efficacy and safety results of a prospective, randomized, double-masked, placebo-controlled clinical trial. Ophthalmology 111:2044-2049
24. Tolentino MJ, McLeod DS, Taomoto M, Otsuji T, Adamis AP, Lutty GA (2002) Pathologic features of vascular endothelial growth factor-induced retinopathy in the nonhuman primate. Am J Ophthalmol 133:373-385
25. Tolentino MJ, Miller JW, Gragoudas ES, Jakobiec FA, Flynn E, Chatzistefanou K, Ferrara N, Adamis AP (1996) Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology 103:1820-1828